SunMax Biotechnology (4728) reported revenue of NT$190.3 million for Oct 2026, +18.2% year on year and -20.3% from the previous month. Revenue for Jan–Oct 2026 was NT$2.06 billion (+22.5% year on year).
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 44 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$190.3 million | +18.2% | -20.3% |
| Sep 2026 | NT$238.8 million | +16.1% | +7.0% |
| Aug 2026 | NT$223.2 million | +48.8% | +0.8% |
| Jul 2026 | NT$221.5 million | +49.7% | -1.5% |
| Jun 2026 | NT$224.8 million | +50.1% | +17.5% |
| May 2026 | NT$191.3 million | +23.8% | -5.4% |
| Apr 2026 | NT$202.1 million | +29.7% | -10.3% |
| Mar 2026 | NT$225.3 million | +20.1% | +95.8% |
| Feb 2026 | NT$115.1 million | -30.3% | -48.7% |
| Jan 2026 | NT$224.4 million | +11.4% | +25.3% |
| Dec 2025 | NT$179.1 million | +20.2% | +6.5% |
| Nov 2025 | NT$168.2 million | +21.6% | +4.5% |
| Oct 2025 | NT$161 million | +1.6% | -21.8% |
| Sep 2025 | NT$205.7 million | +18.9% | +37.2% |
| Aug 2025 | NT$150 million | +0.5% | +1.4% |
| Jul 2025 | NT$148 million | -7.7% | -1.2% |
| Jun 2025 | NT$149.8 million | -4.9% | -3.0% |
| May 2025 | NT$154.5 million | +4.4% | -0.9% |
| Apr 2025 | NT$155.9 million | -0.6% | -16.9% |
| Mar 2025 | NT$187.6 million | -0.8% | +13.6% |
| Feb 2025 | NT$165.1 million | +17.6% | -18.1% |
| Jan 2025 | NT$201.5 million | +105.2% | +35.3% |
| Dec 2024 | NT$149 million | +20.9% | +7.6% |
| Nov 2024 | NT$138.4 million | -5.4% | -12.6% |
| Oct 2024 | NT$158.4 million | +17.3% | -8.4% |
Jan–Oct 2026 cumulative: NT$2.06 billion (+22.5% YoY)
Other Biotech & Medical companies
Compare with peers: SunMax Biotechnology vs PEC / SunMax Biotechnology vs Lotus Pharm / SunMax Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16